



The 65th ASH Annual Meeting Abstracts

PLENARY ABSTRACTS

PLENARY ABSTRACTS

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, MD PhD^{1,2}, Wilfried Roeloffzen, MD PhD³, Meletios A. Dimopoulos, MD PhD⁴, Laura Rosiñol, MD PhD⁵, Marjolein van der Klift, MD PhD⁶, Roberto Mina, MD^{1,2}, Albert Oriol Rocafiguera, MD⁷, Eirini Katodritou, MD⁸, Ka Lung Wu, MD PhD⁹, Paula Rodriguez Otero, MD PhD¹⁰, Roman Hajek, MD^{11,12}, Elisabetta Antonioli, MD¹³, Mark van Duin, PhD¹⁴, Mattia D'Agostino, MD^{2,1}, Joaquin Martinez-Lopez, MD PhD¹⁵, Elena M. van Leeuwen-Segarceanu, MD PhD¹⁶, Paola Tacchetti, MD PhD¹⁷, Niels W.C.J. van de Donk, MD PhD¹⁸, Katja Weisel, MD¹⁹, Luděk Pour, MD²⁰, Jakub Radocha, MD PhD²¹, Angelo Belotti, MD²², Fredrik Schjesvold, MD PhD^{23,24}, Joan Bladé, MD PhD²⁵, Hermann Einsele, MD PhD²⁶, Pieter Sonneveld, MD PhD¹⁴, Mario Boccadoro, MD²⁷, Annemiek Broijl, MD PhD¹⁴

¹ Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

² Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy

³ Department of Hematology, University Medical Center Groningen, Groningen, Netherlands

⁴ Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

⁵ Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain

⁶ Department of Internal Medicine, Amphio Hospital, Breda, Netherlands

⁷ Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

⁸ Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece

⁹ ZNA Stuivenberg, Antwerp, Belgium

¹⁰ Clínica Universidad de Navarra, Pamplona, Spain

¹¹ Department of Haematology, University Hospital Ostrava, Ostrava, Czech Republic

¹² Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

¹³ Hematology Unit, AOU Careggi, Florence, Italy

¹⁴ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

¹⁵ Hematology Department, Hospital Universitario 12 de Octubre, Medicine Department Complutense University, CNIO, Madrid, Spain

¹⁶ Department of Hematology, St. Antonius Hospital, Nieuwegein, Netherlands

¹⁷ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

¹⁸ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

¹⁹ Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

²⁰ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

²¹ 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic

²² Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

²³ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway

²⁴ KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

²⁵ Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain

²⁶ Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

²⁷ European Myeloma Network, EMN, Italy

Background. The current standard treatment for transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM) consists of quadruplet induction with proteasome inhibitors, immunomodulatory agents, dexamethasone and

anti-CD38 monoclonal antibody followed by high-dose melphalan and autologous stem-cell transplant (MEL200-ASCT), with subsequent consolidation. The phase III IsKia trial assessed efficacy and safety of isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) as pre-ASCT induction and post-ASCT consolidation vs KRd.

Methods. TE NDMM pts aged <70 years were enrolled and randomized. IsaKRd pts received 4 28-day cycles of Isa: 10 mg/kg IV days 1, 8, 15, 22 cycle 1, followed by 10 mg/kg days 1, 15 cycles 2-4; K: 20 mg/m² IV day 1 cycle 1, followed by 56 mg/m² IV days 8, 15 cycle 1 and days 1, 8, 15 cycles 2-4; R: 25 mg PO daily days 1-21; d: 40 mg PO days 1, 8, 15, 22; MEL200-ASCT and 4 consolidation cycles with IsaKRd at the same schedule. KRd pts received 4 KRd induction cycles; MEL200-ASCT and 4 KRd consolidation cycles (K, R and d at the same schedule as in the IsaKRd arm). The primary endpoint was the rate of minimal residual disease (MRD) negativity by next-generation sequencing (NGS; 10⁻⁵) after consolidation in the intention-to-treat (ITT) population. MRD was tested in all pts who achieved at least a very good partial response (≥VGPR). Key secondary endpoints were the rate of NGS MRD negativity (10⁻⁵) after induction and PFS. MRD rates were evaluated in an ITT analysis (pts with missing MRD data or who achieved ≤PR were considered as MRD positive). The data cut-off for the analysis was May 22, 2023.

Results. 302 pts were enrolled and randomized (151 in both the IsaKRd and KRd arms). Pt characteristics were well balanced between the two arms: median age was 61 vs 60 years, respectively; 18% vs 19% of pts had high-risk (HiR) cytogenetic abnormalities (CA) [del(17p) and/or t(4;14) and/or t(14;16)]; 9% vs 8% had ≥2 HiR CA [double hit; including del(17p), t(4;14), t(14;16) and gain/amp(1q)]. In ITT analysis, the rates of MRD negativity at the 10⁻⁵ cut-off after consolidation (primary endpoint) were 77% vs 67% (OR 1.67; p=0.049) with IsaKRd vs KRd; the respective rates of MRD negativity at the 10⁻⁶ cut-off were 67% vs 48% (OR 2.29; p<0.001); consistent MRD results were detected by next-generation flow. ≥VGPR after consolidation was 94% in both arms; ≥CR 74% vs 72% and sCR 64% vs 67% in the IsaKRd vs KRd arms. The MRD negativity advantage, both at 10⁻⁵ and 10⁻⁶, was retained in all subgroups analyzed (Figure), with similar benefit in pts with standard-risk (SR) and HiR features. In particular, the 10⁻⁵ MRD negativity rates with IsaKRd were 76% in HiR and 77% in double-hit pts, comparable to the one in SR pts (79%). In the KRd arm, the 10⁻⁵ MRD negativity rates were 58% in HiR and 53% in double-hit pts, inferior to the one in SR pts (70%). The 10⁻⁶ MRD negativity rates with IsaKRd were 72% in HiR, 77% in double-hit pts and 67% in SR pts. The MRD negativity rate after induction (first key secondary endpoint) was also significantly higher with IsaKRd vs KRd (10⁻⁵: 45% vs 26%, OR 2.34, p<0.001; 10⁻⁶: 27% vs 14%, OR 2.36, p=0.004), with a consistent benefit in all subgroups. After induction, the MRD negativity rates in HiR and double-hit pts treated with IsaKRd were: 10⁻⁵, HiR 60%, double-hit 54%; 10⁻⁶, HiR 40%, double-hit 31%. The MRD negativity rates after ASCT were also significantly better with IsaKRd vs KRd (10⁻⁵: 64% vs 49%, OR 1.93, p=0.006; 10⁻⁶: 52% vs 27%, OR 3.01, p<0.001), with a consistent advantage in all subgroups. At the current follow-up (median, 20 months, IQR 18-23), there was no difference in PFS (95% at 1 year in both arms). 55% of pts had ≥1 hematologic adverse events (AEs) with IsaKRd vs 43% with KRd; main grade 3-4 hematologic AEs in IsaKRd vs KRd were neutropenia (37% vs 22%) and thrombocytopenia (15% vs 17%). 41% of pts had ≥1 non-hematologic AEs with IsaKRd vs 37% with KRd, including infections (16% vs 12%), gastrointestinal (7% vs 5%), vascular (2% vs 7%) and cardiac events (1% vs 4%). Discontinuation for toxicity was 6% in IsaKRd vs 5% in KRd arms; treatment-related deaths were 4 with IsaKRd (2 COVID, 1 pneumonia, 1 pulmonary embolism) and 1 with KRd (septic shock).



Conclusion. In TE NDMM pts, the addition of isatuximab to KRd induction and consolidation significantly increased MRD negativity rates in every treatment phase as compared to KRd, with no new safety concerns. This benefit was retained in HiR pts.

Disclosures Gay: Pfizer: Honoraria, Other: Advisory board; Amgen: Honoraria, Other: Advisory board; Takeda: Honoraria, Other: Advisory board; Sanofi: Honoraria, Other: Advisory board; Bristol Myers Squibb/Celgene: Honoraria, Other: Advisory board; Oncopeptides: Other: Advisory board; Janssen: Honoraria, Other: Advisory board; Roche: Other: Advisory board; GlaxoSmithKline: Honoraria, Other: Advisory board; AbbVie: Honoraria, Other: Advisory board. **Roeloffzen:** Amgen: Other: Travel grants, honoraria or advisory board (not personal); Sanofi: Other: Travel grants, honoraria or advisory board (not personal); AbbVie: Other: Travel grants, honoraria or advisory board (not personal); Bristol Myers Squibb: Other: Travel grants, honoraria or advisory board (not personal); Janssen: Other: Travel grants, honoraria or advisory board (not personal). **Dimopoulos:** AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. **Rosñol:** Amgen: Other: Honoraria for lectures; Takeda: Other: Honoraria for lectures; GlaxoSmithKline: Other: Honoraria for lectures; Sanofi: Other: Honoraria for lectures; Bristol Myers Squibb/Celgene: Other: Honoraria for lectures; Janssen: Other: Honoraria for lectures. **Mina:** Pfizer: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. **Rocafiguera:** Oncopeptides: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or

advisory committees; *Pfizer*: Membership on an entity's Board of Directors or advisory committees; *BMS*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Menarini*: Membership on an entity's Board of Directors or advisory committees; *Janssen*: Honoraria, Membership on an entity's Board of Directors or advisory committees. **Katodritou**: *Janssen Cilag*, *Amgen*, *Abbvie*, *Pfizer*, *GSK*, *Takeda*, *Sanofi*, *Karyopharm*: Honoraria, Research Funding. **Rodriguez Otero**: *AbbVie*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *GlaxoSmithKline*: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; *Pfizer*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel grants; *Amgen*: Other: Honoraria for lectures; *Regeneron*: Other: Honoraria for lectures; *Oncopeptides*: Membership on an entity's Board of Directors or advisory committees; *Roche*: Consultancy; *Sanofi*: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; *Janssen*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; *Bristol Myers Squibb*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures. **Hajek**: *Amgen*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding; *Celgene*: Consultancy, Honoraria, Other: Support for attending meetings and/or travel, Research Funding; *Janssen*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding; *Bristol Myers Squibb*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Novartis*: Consultancy, Research Funding; *Takeda*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding; *Sanofi*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *Oncopeptides*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *GlaxoSmithKline*: Membership on an entity's Board of Directors or advisory committees; *AbbVie*: Consultancy; *PharmaMar*: Consultancy, Honoraria. **D'Agostino**: *Bristol Myers Squibb*: Membership on an entity's Board of Directors or advisory committees; *Janssen*: Other: Honoraria for lectures; *Sanofi*: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; *GlaxoSmithKline*: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures. **Tacchetti**: *Takeda*: Honoraria; *Amgen*: Honoraria; *Bristol Myers Squibb/Celgene*: Honoraria; *Pfizer*: Honoraria; *Sanofi*: Honoraria; *GlaxoSmithKline*: Honoraria; *Janssen*: Honoraria. **van de Donk**: *Bristol Myers Squibb*: Other: Advisory boards (all paid to institution), Research Funding; *Servier*: Other: Advisory boards (all paid to institution); *Adaptive*: Other: Advisory boards (all paid to institution); *Pfizer*: Other: Advisory boards (all paid to institution); *Roche*: Other: Advisory boards (all paid to institution); *Novartis*: Other: Advisory boards (all paid to institution); *Janssen Pharmaceuticals*: Other: Advisory boards (all paid to institution), Research Funding; *Amgen*: Other: Advisory boards (all paid to institution), Research Funding; *Bayer*: Other: Advisory boards (all paid to institution); *Novartis*: Research Funding; *AbbVie*: Other: Advisory boards (all paid to institution); *Takeda*: Other: Advisory boards (all paid to institution); *Celgene*: Other: Advisory boards (all paid to institution), Research Funding; *Cellceptis*: Research Funding. **Weisel**: *Amgen*: Consultancy, Honoraria, Other: Research grant to institution; *Adaptive Biotech*: Consultancy, Honoraria; *Pfizer*: Consultancy, Honoraria; *AbbVie*: Consultancy, Honoraria, Other: Research grant to institution; *Janssen*: Consultancy, Honoraria, Other: Research grant to institution; *GlaxoSmithKline*: Consultancy, Honoraria, Other: Research grant to institution; *AstraZeneca*: Honoraria; *Bristol Myers Squibb/Celgene*: Consultancy, Honoraria, Other: Research grant to institution; *Takeda*: Consultancy, Honoraria, Other: Research grant; *Sanofi*: Consultancy, Honoraria, Other: Research grant to institution; *Stemline*: Honoraria; *Oncopeptides*: Consultancy, Honoraria; *Novartis*: Honoraria; *Roche Pharma*: Consultancy, Honoraria; *Karyopharm*: Consultancy, Honoraria; *Menarini*: Consultancy, Honoraria; *BeiGene*: Consultancy, Honoraria. **Radocha**: *Sanofi*: Consultancy, Honoraria, Other: Travel expenses; *Janssen*: Consultancy, Honoraria, Other: Travel expenses; *Amgen*: Consultancy, Honoraria; *GlaxoSmithKline*: Consultancy, Honoraria; *Bristol Myers Squibb*: Consultancy, Honoraria, Other: Travel expenses. **Belotti**: *Janssen*: Membership on an entity's Board of Directors or advisory committees; *Pfizer*: Membership on an entity's Board of Directors or advisory committees; *Takeda*: Membership on an entity's Board of Directors or advisory committees; *GlaxoSmithKline*: Membership on an entity's Board of Directors or advisory committees; *Amgen*: Membership on an entity's Board of Directors or advisory committees. **Schjesvold**: *Pfizer*: Other: Honoraria for lectures and educational material; *Daiichi Sankyo*: Other: Honoraria for lectures and educational material; *Skylite DX*: Other: Honoraria for lectures and educational material; *Novartis*: Other: Honoraria for lectures and educational material; *Targovax*: Research Funding; *Oncopeptides*: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; *Celgene*: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; *Abbvie*: Consultancy, Other: Honoraria for lectures and educational material; *Bristol Myers Squibb*: Consultancy, Other: Honoraria for lectures and educational material; *Sanofi*: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; *GlaxoSmithKline*: Consultancy, Honoraria, Research Funding; *Takeda*: Consultancy, Other: Honoraria for lectures and educational material; *Janssen-Cilag*: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; *Amgen*: Other: Honoraria for lectures and educational material; *Schain*: Other: Honoraria for lectures and educational material. **Bladé**: *Sanofi*: Other: Honoraria for lectures; *Janssen*: Other: Honoraria for lectures; *Amgen*: Other: Honoraria for lectures; *Celgene/Bristol Myers Squibb*: Other: Honoraria for lectures. **Einsele**: *Janssen*: Honoraria, Other: Consulting or advisory role, Travel support, Research Funding; *Takeda*: Honoraria, Other: Consulting or advisory role, Travel support; *Amgen*: Honoraria, Other: Consulting or advisory role, Travel support, Research Funding; *Novartis*: Honoraria, Other: Consulting or advisory role, Travel support; *GlaxoSmithKline*: Honoraria, Other: Consulting or advisory role, Travel support, Research Funding; *Sanofi*: Honoraria, Other: Consulting or advisory role, Travel support, Research Funding; *Bristol Myers Squibb/Celgene*: Honoraria, Other: Consulting or advisory role, Travel support, Research Funding. **Sonneveld**: *Pfizer*: Membership on an entity's Board of Directors or advisory committees; *Karyopharm*: Membership on an entity's Board of Directors

or advisory committees, Research Funding; *Janssen*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Celgene*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Bristol Myers Squibb*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Amgen*: Membership on an entity's Board of Directors or advisory committees, Research Funding. **Boccardo**: *Mundipharma*: Research Funding; *GlaxoSmithKline*: Membership on an entity's Board of Directors or advisory committees; *AbbVie*: Honoraria; *Bristol Myers Squibb*: Honoraria, Research Funding; *Novartis*: Honoraria, Research Funding; *Janssen*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Amgen*: Honoraria, Research Funding; *Celgene*: Honoraria, Research Funding; *Sanofi*: Honoraria, Research Funding. **Broijl**: *Amgen*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Bristol Myers Squibb*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Sanofi*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Janssen*: Honoraria, Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure: This presentation includes information or discussion of the off-label use of a drug or drugs for the treatment of multiple myeloma: isatuximab, carfilzomib, lenalidomide, and dexamethasone.

Panel A. Subgroup analysis of MRD negativity after consolidation: 10^{-5} cut-offPanel B. Subgroup analysis of MRD negativity after consolidation: 10^{-6} cut-off

Abbreviations. MRD, minimal residual disease; OR, odds ratio; CI, confidence interval; p, p-value; R-ISS, Revised International Staging System stage; R2-ISS, Second Revision of the International Staging System stage; K, carfilzomib; R, lenalidomide; d, dexamethasone; Isa, isatuximab.

Figure 1

<https://doi.org/10.1182/blood-2023-177546>